Nuvation Bio names Philippe Sauvage CFO as company readies for NDA submission
Plus: Terry Kohler becomes CFO of Optinose and Mike Wourms COO at Genezen
Cancer company Nuvation Bio Inc. (NYSE:NUVB) hired Philippe Sauvage as CFO. Sauvage was global head of operations and access at Sanofi (Euronext:SAN; NASDAQ:SNY), where he held commercial and finance roles over 12 years that included CFO of Sanofi North America. Nuvation is planning an NDA submission in the fourth quarter for lead program taletrectinib adipate to treat ROS1-positive non-small cell lung cancer.
Terry Kohler became CFO of OptiNose Inc. (NASDAQ:OPTN), which is developing therapies for diseases of the ears, nose and throat. Kohler was CFO of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA). In May, FDA expanded the label of OptiNose’s drug-device combo, Xhance fluticasone propionate, to include chronic rhinosinusitis with or without polyps, a larger indication than its 2017 approval for nasal polyps...